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Abstract
Background: Insulinoma is a rare diagnosis in the general population with estimates of 1 in 250,000 people per
year. Reports of these pancreatic islet cell tumors are even more unusual in children and adolescents. Chronic
hypoglycemia due to an insulinoma often presents with neuroglycopenic symptoms that can easily be overlooked,
especially in adolescents where nonspecific complaints are common. This may result in delayed diagnosis with
prolonged periods of untreated hypoglycemia and associated complications. The rarity of pediatric insulinoma,
vagueness of presenting symptoms, and challenge of tumor localization make insulinoma a true diagnostic
quandary for clinicians.
Case Presentation: In this report, we present a 15-year-old female who visited her primary care provider
complaining of intermittent episodes of altered mental status including fatigue, irritability, and poor concentration.
Her outpatient management included routine laboratory studies, drug screening, electroencephalogram (EEG),
valproic acid initiation, CT scan of the abdomen, and endoscopic ultrasound with documentation of hypoglycemia,
but otherwise inconclusive results. The patient was admitted to a tertiary children’s hospital with severe refractory
hypoglycemia 8 months after the initial evaluation. A serum critical sample was obtained and magnetic resonance
imaging (MRI) of the abdomen performed which confirmed the presence of a pancreatic mass ultimately identified
as an insulinoma. She went on to have surgical resection of her tumor resulting in complete resolution of her
hypoglycemia and associated symptoms.
Conclusion: Within this report we demonstrate the importance of being vigilant for fasting hypoglycemia
secondary to insulinoma even when the patient presents with nonspecific symptoms such as fatigue, irritability, or
problems with concentration. If these neuroglycopenic complaints are unnoticed or misdiagnosed, patients with a
potentially curable disease are put at risk of neurologic injury, or even death, due to untreated severe
hypoglycemia.
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Background
An adolescent presenting with changes in behavior is not
unusual in pediatric practice. Common suspects are rou-
tine teenage behavior, mental illness, or substance abuse.
On the contrary, hypoglycemia, especially due to an insulin
producing tumor, can easily be overlooked. Despite being
the most common functioning neoplasm of the pancreas,
insulinomas are rare in the general population with
estimates at 1 in 250,000 people per year [1]. Epidemiology
studies in pediatrics are even more limited. Insulinomas
are comprised of pancreatic beta islet cells that produce
excess amounts of endogenous insulin [2]. This inappro-
priate insulin secretion results in hypoglycemia with its
associated neurogenic and neuroglycopenic symptoms.
With prolonged and repeated hypoglycemia, neurogenic
symptoms are minimized and nonspecific neuroglycopenic
symptoms predominate [3]. We present the case of an
adolescent female who delayed seeking medical attention
given the ambiguity of symptoms and once assessed by a
medical provider had a prolonged evaluation resulting in
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curative surgery more than 8 months after symptom onset.
This case highlights the importance of awareness and rec-
ognition of neuroglycopenic symptoms in order to prevent
undetected chronic hypoglycemia.
Case Presentation
A 15-year-old girl presented to her primary care provider
with episodes of altered behavior. She reported a 30-
minute period of fatigue, confusion, poor concentration,
irritability, and “staring off” which was noted by parents
while the patient was getting ready for school. The patient
herself did not recall the event. Her parents had witnessed
several similar events lasting up to 30 min, at least once
per week, in the morning, for the past 5 months. Their
daughter’s symptoms would resolve after eating breakfast.
They had not sought medical care previously, assuming
her behavior was related to early morning drowsiness.
When the frequency of these episodes increased to several
times per week, they presented to their primary care
physician. Following her primary care visit, the patient
was scheduled for an outpatient EEG after BMP, thyroid
studies, and UDS which were normal. The patient became
unresponsive during the EEG study and was referred to
the local hospital with the following laboratory data when
she was symptomatic: point-of-care glucose 36 mg/dL
(65–110), insulin 36.8 uIU/mL (2.6–24.9), C-peptide
4.6 ng/mL (1.1–4.4), and betahydroxybutyrate 0.6 mg/dL
(0.2–2.8). Her mental status immediately improved with
intravenous dextrose. In search of an insulin-producing
mass, she underwent abdominal CT with contrast which
was negative per the local radiologist’s report. Her EEG
was interpreted as abnormal prompting the initiation of
valproic acid therapy for potential seizure activity. She was
discharged home from the emergency room with a gluc-
ometer and planned neurology follow-up. An outpatient
endoscopic ultrasound was pursued as another attempt to
localize any potential insulin producing mass, and this too
was unremarkable. She was subsequently referred for sub-
specialty consultation with a pediatric endocrinologist.
Prior to her scheduled endocrinology appointment, she
was admitted to a tertiary care pediatric center due to near
daily episodes of hypoglycemia associated with altered
mental status. The patient became hypoglycemic over-
night while fasting in less than 6 h (Fig. 1). A critical sam-
ple was obtained and confirmed hyperinsulinemic
hypoglycemia (Table 1). Testing for sulfonylurea ingestion
was performed and the result was negative. An MRI of the
abdomen revealed a 0.9 × 1.1 × 1.3 cm pancreatic mass
(Fig. 2). Valproic acid was stopped and her hypoglycemia
medically managed successfully with diazoxide 150 mg
orally 3 times per day (8 mg/kg/day) and two tablespoons
of cornstarch at bedtime. She ultimately underwent lap-
aroscopic distal pancreatectomy with pathologic examin-
ation of the mass confirming a benign insulinoma (Fig. 3).
She had mild hyperglycemia post-operatively which re-
solved within 48 h without insulin therapy and was
discharged home on post-operative day three. Gene se-
quencing by using DNA from a peripheral blood sample
for multiple endocrine neoplasia was negative.. The pa-
tient remained euglycemic, asymptomatic, and lost 15 kg
in the 10 months following tumor resection which
dropped her BMI from the 87th to 45th percentile. A
follow up EEG was performed and was completely nor-
mal. She is now considered cured. The time from onset of
symptoms to correct diagnosis, tumor localization, and
surgical management was approximately 8 months.
Fig. 1 Point of care glucose trend during supervised fast. Our patient’s
point-of-care glucose monitoring during hospital admission showing a
rapid decline to 40 mg/dl 6 h after initiation of fasting at 22:00




Glucose (mg/dL) 43 (65–110)
Insulin (mcIU/mL) 38.1 (2–18)
C-peptide (mcIU/mL) 4.1 (0.6–6.3)
Beta-Hydroxybutyrate (mcmol/L) <100 (0–269)
Cortisol (mcg/dL) 4.4 (7–25)
Free fatty acids (mmol/L) 0.08
Human growth hormone (ng/mL) 0.2 (0–7)
B.
Ammonia (mcmol/L) <9 (4–33)
TSH (mcIU/mL) 2.19 (0.35–5.5)
Free T4 (ng/dL) 1.0 (0.8–1.9)
Cortisol 60 min after 250mcg
cosyntropin (mcg/dL)
22.1
Sulfonylurea serum level Undetectable
Insulin antibody level Undetectable
A. Critical sample results reveal hyperinsulinemic hypoglycemia.
B. Additional studies obtained when euglycemic
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Discussion
Insulinomas are tumors composed of pancreatic beta-islet
cells which produce excess endogenous insulin resulting in
intermittent hypoglycemia. Epidemiologic studies in the
United States estimate the incidence at approximately four
insulinoma cases per million patients per year. The typical
age at diagnosis is reported in the fifth decade of life with a
slightly higher female prevalence [1]. However, insulinomas
have been diagnosed in patients of all ages, including chil-
dren and adolescents, though congenital hyperinsulinism
remains the most common etiology for pediatric hype-
rinsulinemic hypoglycemia. Given the rarity of insulinoma
in youth, its incidence in children has not been estimated
[4]. Insulinomas are most often small (diameter less than
ba  
Fig. 2 Result of MRI of the abdomen. Axial T1 weighted pre-contrast (a) and post-contrast (b) MRI images demonstrate a round enhancing lesion
in the body of the pancreas (arrowhead)
a b
c d
Fig. 3 Gross and microscopic images of resected specimen. a Gross pancreatic specimen following laparoscopic distal pancreatectomy. External
surface showing orange ink applied to the area in which a palpable mass was appreciated (circle). b Gross pancreatic body specimen showing
cut surface with 1 cm hyperpigmented nodule (arrowhead), which presents a smooth surface distinct from adjacent normal lobulated pancreas.
c Histologic section (H&E stain, 40x magnification) of the tumor showing an intact capsule separating it from normal pancreatic tissue.
d Synaptophysin immunostain: diffuse positive staining present in tumor cells
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2 cm), localized, benign, and sporadic [5]. However, up to
10 % of insulinomas occur as a component of multiple
endocrine neoplasia type 1 (MEN1), an autosomal domin-
ant disorder resulting from a mutation in the MEN1 gene
[1]. The list of MEN1 mutations discovered continues to
grow, with over 1,300 mutations currently reported. [6].
Despite their typically benign anatomic characteristics,
the functionality of insulinomas can result in significant
morbidity. As a result of their unregulated insulin secre-
tion, the patients with insulinoma have impaired hepatic
glycogenolysis, gluconeogenesis, and ketogenesis result-
ing in severe, recurrent hypoglycemia. In response to the
hypoglycemia two categories of symptoms are observed:
neurogenic and neuroglycopenic (Table 2) [7]. Neuro-
genic symptoms often can be quickly be identified as cli-
nicians and even patients associate them with low blood
sugar. However, with prolonged, chronic hypoglycemia
the adrenergic response can be blunted, resulting in a
phenomenon known as “hypoglycemia-associated auto-
nomic failure.” This occurs primarily because the gly-
cemic threshold for initiation of the autonomic response
is shifted to a lower serum glucose concentration. This
results in patients having hypoglycemia unawareness with
the first evidence of hypoglycemia being neuroglycopenic
symptoms. Neuroglycopenic symptoms are a result of in-
adequate glucose for utilization by cerebral tissues and
can be exceptionally vague. However, if not addressed,
mild symptoms can progress to the most severe findings
of neuroglycopenia, including coma and death [3].
Due to the ambiguity of presenting symptoms, the
diagnosis of insulinoma is often elusive. It is not uncom-
mon for insulinoma patients to be diagnosed with some
form of neurologic disorder which resolves once their
insulinoma is found and appropriately resected. Com-
mon alternative diagnoses include seizure disorders and
cerebrovascular accidents or transient ischemic attacks.
Diagnosis can be delayed for years with one study de-
scribing a mean time to diagnosis of 24 months with a
range from 1 month to 30 years from symptom onset to
surgical resection in patients ranging from 17 to 59 years
of age [8]. The pediatric population represents an even
more difficult population for making the diagnosis based
on neuroglycopenic symptoms. Younger children may
not be able to appropriately describe their symptoms
and therefore it is left to the caregivers and medical pro-
viders to interpret clinical signs [9]. For teenagers,
changes in mood and behavior can often been be per-
ceived as a routine part of adolescence. Even if their al-
tered mental status is more pronounced, other diagnoses
such as substance abuse, trauma, or epilepsy may be
deemed more likely [10, 11].
Furthermore, if there is clinical suspicion for hyperin-
sulinemic hypoglycemia, laboratory confirmation itself
can be difficult. The classic clinical diagnosis relies on satis-
fying the criteria of Whipple’s triad which include 1) low
serum glucose 2) symptoms consistent with hypoglycemia,
and 3) immediate resolution of symptoms following treat-
ment with carbohydrate [12]. Laboratory assessment should
include serum glucose, insulin, and C-peptide or pro-insulin
levels which should demonstrate hypoglycemia with in-
appropriately normal or elevated insulin concentrations. Ele-
vated C-peptide or pro-insulin levels support endogenous
insulin production where as these values would be sup-
pressed with exogenous insulin administration (factitious
hypoglycemia) [13]. Prolonged fasting may be necessary to
induce and capture the biochemical evidence necessary to
document hyperinsulinemic hypoglycemia [14]. If identified,
hyperinsulinemic hypoglycemia outside of the neonatal
period is suggestive of insulinoma, though recurrent sulfo-
nylurea ingestion and stimulating insulin receptor mutation
can present with comparable laboratory findings [15].
Localization of the tumor represents an additional
challenge in the diagnosis of insulinoma. Given their
small size, multiple imaging modalities may be required
before the tumor is located [16]. Techniques that have
been used are transabdominal and endoscopic ultra-
sound, CT, MRI, octreotide scan, calcium stimulation
with angiography, and more recently 18 F-DOPA PET/
CT. No single modality has been proven the gold stand-
ard and influences such as cost, sensitivity, operator skill,
and availability of equipment must be considered. Typic-
ally, noninvasive studies are pursued initially with some
Table 2 Symptoms of hypoglycemia: neurogenic vs. neuroglycopenic
Neurogenic Symptoms
(Autonomic Nervous System Stimulation)
Neuroglycopenic Symptoms
(Inadequate Glucose for Cerebral Use)
Palpitations Fatigue
Diaphoresis Personality change
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combination of ultrasound and CT or MRI. If these are
unsuccessful then more invasive techniques may follow
[4, 17–19]. Tissue confirmation of the diagnosis of insuli-
noma can be achieved by a needle-core biopsy, laparo-
scopic biopsy or surgical excision of the tumor.
Histologically, insulinoma is comprised of monomorphic
tumor cells with the nuclei demonstrating stippled “salt
and pepper” chromatin pattern typical of neuroendocrine
tumors. Expression of chromogranin A, synaptophysin,
and insulin can be demonstrated by immunohistochemis-
try, which further aids in confirming the diagnosis [8, 11].
Surgical resection is the standard of care for definitive
insulinoma management. However, initial treatment for
childhood insulinoma may focus on dietary modification
to prevent hypoglycemia [16]. Medical therapies such as
diazoxide and octreotide have been used successfully to
prevent hypoglycemia in the perioperative period and
for patients who are poor surgical candidates [20, 21].
Pancreas sparing techniques, including tumor enucle-
ation and partial pancreatectomies, performed either
openly or laparoscopically have been described in chil-
dren with overall excellent cure rates and low risk of
morbidity and mortality [22–24].
Conclusion
Despite its rarity, clinicians must consider insulinoma in
the differential diagnosis of hypoglycemia when address-
ing nonspecific concerns such has fatigue, irritability, or
problems with concentration. This is especially true if
symptoms are exacerbated by periods of fasting, such as
early in the morning or accompanied by excessive
weight gain. Our case highlights that a high index of sus-
picion is particularly critical in the adolescent population
where vague somatic complaints or changes in behavior
can easily be disregarded by families and the clinician
alike as inconsequential. It is absolutely paramount that
providers be aware of not only the more recognizable
neurogenic symptoms, but also the neuroglycopenic
findings in hypoglycemia and educate their patients and
families accordingly. Our patient also taught us that
there must be consideration of hypoglycemia in all pa-
tients presenting with changes in mental status. The key
to timely diagnosis of insulinoma is to consider the pos-
sibility of hypoglycemia early in the patient’s evaluation,
because even then, the challenge of obtaining diagnostic
laboratory assays and imaging studies remains. Disre-
garding or misconceiving insulinoma patients’ neurogly-
copenic complaints will delay their diagnosis further and
can result in devastating neurologic consequences due
to their recurrent, untreated severe hypoglycemia.
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